Alterations in structural connectivity may contribute both to the occurrence of tics in Gilles de la Tourette syndrome and to their subsequent control.

2012; 27: 339–40. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, Salsone M, et al. Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord 2011; 26: 807–12. Cerasa A, Pugliese P, Messina D, Morelli M, Gioia MC, Salsone M, et al. Prefrontal alterations in Parkinson’s disease with levodopainduced dyskinesia during fMRI motor task. Mov Disord 2012; 27: 364–71. Cerasa A, Koch G, Donzuso G, et al. A network centred on the inferior frontal cortex is critically involved in levodopainduced dyskinesias. Brain 2015; 138: 414–27. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000, 47 (Suppl 1): 2–9. Gross RE, Lombardi WJ, Lang AE, Duff J, Hutchison WD, Saint-Cyr JA, et al. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson’s disease. Brain 1999; 122: 405–16. Lees A, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias and Melvin Yahr. Mov Disord 2015; 30: 3–6. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol 2000, 47 (4 Suppl 1): 22–32. Page RD, Sambrook MA, Crossman AR. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine-treated parkinsonian monkey. Neuroscience 1993; 55: 147–65. Périer C, Tremblay L, Féger J, Hirsch EC. Behavioral consequences of bicuculline injection in the subthalamic nucleus and the zona incerta in rat. J Neurosci 2002; 22: 8711–19. Rascol O, Sabatini U, Brefel C, Fabre N, Rai S, Senard JM, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 1998; 121: 527–33.